Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress

Journal of Alzheimer's Disease

Volumn 28, Issue 1, 2012, Pages 147-161

  Gallagher, Joseph J ^a   Finnegan, Mary E ^b   Grehan, Belinda ^a   Dobson, Jon ^c,d   Collingwood, Joanna F ^b,c   Lynch, Marina A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c KEELE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Alzheimer's disease; iron; microglia; oxidative stress; spectrometry; X ray fluorescence

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CD11B ANTIGEN; CD68 ANTIGEN; IRON; IRON OXIDE; MAGNETITE; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; FEMALE; HEMISPHERE; HISTOPATHOLOGY; MICROGLIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; X RAY ABSORPTION SPECTROSCOPY;

EID: 84855801337     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110614     Document Type: Article

References (70)

1. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863-873. (Pubitemid 39482155)
2. Aisen P, Enns C, Wessling-Resnick M (2001) Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 33, 940-959. (Pubitemid 32706687)
3. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY (1984) Transferrin receptor on endothelium of brain capillaries. Nature 312, 162-163. (Pubitemid 14000081)
4. Burdo JR, Connor JR (2003) Brain iron uptake and homeostatic mechanisms: An overview. Biometals 16, 63-75. (Pubitemid 36140216)
5. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Canizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, PandolfoM(1996) Friedreichs ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427. (Pubitemid 26089479)
6. Thompson PM, Hua X, Leow AD, Lee S, Klunder AD, Toga AW, Lepore N, Chou YY, Brun C, Chiang MC, Barysheva M, Jack CR, Bernstein MA, Britson PJ, Ward CP, Whitwell JL, Borowski B, Fleisher AS, Fox NC, Boyes RG, Barnes J, Harvey D, Kornak J, Schuff N, Boreta L, Alexander GE, Weiner MW, Initi AsDN (2008) 3D characterization of brain atrophy in Alzheimers disease and mild cognitive impairment using tensor-based morphometry. Neuroimage 41, 19-34.
7. Selkoe DJ (1994) Alzheimers disease: A central role for amyloid. J Neuropathol Exp Neurol 53, 438-447. (Pubitemid 24276802)
8. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539. (Pubitemid 34288854)
9. Wang X, Su B, Fujioka H, ZhuX(2008) Dynamin-like protein reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimers disease patients. Am J Pathol 173, 470-482.
10. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimers disease. Science 307, 1282-1288. (Pubitemid 40299973)
11. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501-1508. (Pubitemid 46685921)
12. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimers disease:Achronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152, 871-877. (Pubitemid 28173347)
13. Smith MA, Perry G, Pryor WA (2002) Causes and consequences of oxidative stress in Alzheimers disease. Free Radic Biol Med 32, 1049. (Pubitemid 34603341)
14. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimers disease. Glia 7, 75-83.
15. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, 3rd, Araoz C (1989) Brain interleukin and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86, 7611-7615. (Pubitemid 19254506)
16. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767. (Pubitemid 32678256)
17. Beal MF (2005) Oxidative damage as an early marker of Alzheimers disease and mild cognitive impairment. Neurobiol Aging 26, 585-586. (Pubitemid 40228749)
18. Wang Q, Rowan MJ, AnwylR(2004) Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 24, 6049-6056. (Pubitemid 38891095)
19. Lue LF, Brachova L, Civin WH, Rogers J (1996) Inflammation, Abeta deposition, and neurofibrillary tangle formation as correlates of Alzheimers disease neurodegeneration. J Neuropathol Exp Neurol 55, 1083-1088. (Pubitemid 26338020)
20. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimers disease. Nature 451, 720-724. (Pubitemid 351220570)
21. Hallgren B, Sourander P (1958) The effect of age on the nonhaemin iron in the human brain. J Neurochem 3, 41-51.
22. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimers disease senile plaques. J Neurol Sci 158, 47-52. (Pubitemid 28277534)
23. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J (2006) Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimers disease. J Struct Biol 155, 30-37. (Pubitemid 43867313)
24. Collingwood J, Dobson J (2006) Mapping and characterization of iron compounds in Alzheimers tissue. J Alzheimers Dis 10, 215-222. (Pubitemid 44763994)
25. Connor JR, Menzies SL, St Martin SM, Mufson EJ (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimers diseased brains. J Neurosci Res 31, 75-83.
26. Smith MA, Zhu XW, Tabaton M, Liu G, McKeel DW, Cohen ML, Wang XL, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A, Perry G (2010) Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19, 363-372.
27. Kirschvink JL, Kobayashikirschvink A, Woodford BJ (1992) Magnetite biomineralization in the human brain. Proc Natl Acad Sci U S A 89, 7683-7687.
28. Hautot D, Pankhurst QA, Khan N, Dobson J (2003) Preliminary evaluation of nanoscale biogenic magnetite in Alzheimers disease brain tissue. Proc R Soc Lond 270, S62-S64. (Pubitemid 36960316)
29. Collingwood JF, Mikhaylova A, Davidson M, Batich C, Streit WJ, Terry J, Dobson J (2005) In situ characterization and mapping of iron compounds in Alzheimers disease tissue. J Alzheimers Dis 7, 267-272. (Pubitemid 41206937)
30. Collingwood JF, Chong RK, Kasama T, Cervera-Gontard L, Dunin-Borkowski RE, Perry G, Posfai M, Siedlak SL, Simpson ET, Smith MA, Dobson J (2008) Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimers plaque core material. J Alzheimers Dis 14, 235-245. (Pubitemid 352040039)
31. Quintana C, Cowley JM, Marhic C (2004) Electron nanodiffraction and high-resolution electron microscopy studies of the structure and composition of physiological and pathological ferritin. J Struct Biol 147, 166-178. (Pubitemid 38757512)
32. Dobson J (2004) Magnetic iron compounds in neurological disorders. Ann N Y Acad Sci 1012, 183-192. (Pubitemid 38453526)
33. Mikhaylova A, Davidson M, Toastmann H, Channell JET, Guyodo Y, Batich C, Dobson J (2005) Detection, identification and mapping of iron anomalies in brain tissue using X-ray absorption spectroscopy. J R Soc Interface 2, 33-37.
34. Khan A, Dobson JP, Exley C (2006) Redox cycling of iron by Abeta42. Free Radic Biol Med 40, 557-569.
35. Wilcock DM, Gordon MN, Morgan D (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 1, 1591-1595.
36. Lyons A, Griffin RJ, Costelloe CE, Clarke RM, Lynch MA (2007) IL-4 attenuates the neuroinflammation induced by amyloid-beta in vivo and in vitro. J Neurochem 101, 771-781. (Pubitemid 46633315)
37. Downer EJ, Cowley TR, Lyons A, Mills KH, Berezin V, Bock E, Lynch MA (2010) A novel anti-inflammatory role of NCAM-derived mimetic peptide, FGL. Neurobiol Aging 31, 118-128.
38. Hautot D, Pankhurst Q, Dobson J (2005) Superconducting quantum interference device measurements of dilute magnetic materials in biological samples. Re Sc Instrum 76.
39. Mosselmans JFW, Quinn PD, Dent AJ, Cavill SA, Moreno SD, Peach A, Leicester PJ, Keylock SJ, Gregory SR, Atkinson KD, Rosell JR (2009) I18 -the microfocus spectroscopy beamline at the Diamond Light Source. J Synchrotron Radiat 16, 818-824.
40. Soĺe VA, Papillon E, Cotte M, Walter P, Susini J (2007) A multiplatform code for the analysis of energy-dispersive Xray fluorescence spectra. Spectrochim Acta B 62, 63-68.
41. Ravel B, Newville M (2005) ATHENA, ARTEMIS, HEPHAESTUS: Data analysis for X-ray absorption spectroscopy using IFEFFIT. J Synchrotron Radiat 12, 537-541. (Pubitemid 41557599)
42. Ruan L, Kang Z, Pei G, Le Y (2009) Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimers disease. Curr Alzheimer Res 6, 531-540.
43. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, FroschMP(2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24, 516-524. (Pubitemid 44716680)
44. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, OCallaghan JP, Morgan D (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173, 183-195. (Pubitemid 34151370)
45. Sayre LM, Perry G, Harris PL, LiuY, Schubert KA, SmithMA (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimers disease: A central role for bound transition metals. J Neurochem 74, 270-279. (Pubitemid 30012778)
46. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63, 793-807. (Pubitemid 24266591)
47. Leskovjan AC, Kretlow A, Lanzirotti A, Barrea R, Vogt S, Miller LM (2011) Increased brain iron coincides with early plaque formation in a mouse model of Alzheimers disease. Neuroimage 55, 32-38.
48. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, SmithMA(2001) Mitochondrial abnormalities in Alzheimers disease. J Neurosci 21, 3017-3023.
49. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ (1997) Global prevalence of putative haemochromatosis mutations. J Med Genet 34, 275-278. (Pubitemid 27208030)
50. Connor JR, Milward EA, Moalem S, Sampietro M, Boyer P, Percy ME, Vergani C, Scott RJ, Chorney M (2001) Is hemochromatosis a risk factor for Alzheimers disease? J Alzheimers Dis 3, 471-477. (Pubitemid 33031803)
51. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX (2002) Overexpression of Alzheimers disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 277, 44670-44676. (Pubitemid 36159056)
52. Lyubartseva G, Smith JL, Markesbery WR, Lovell MA(2010) Alterations of zinc transporter proteinsZnT-1, ZnT-4 andZnT-in preclinical Alzheimers disease brain. Brain Pathol 20, 343-350.
53. Zhang LH, Wang X, Stoltenberg M, Danscher G, Huang L, Wang ZY (2008) Abundant expression of zinc transporters in the amyloid plaques of Alzheimers disease brain. Brain Res Bull 77, 55-60.
54. Deibel MA, Ehmann WD, Markesbery WR (1996) Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimers disease: Possible relation to oxidative stress. J Neurol Sci 143, 137-142. (Pubitemid 26402800)
55. Lovell MA, Smith JL, Xiong S, MarkesberyWR(2005) Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage Alzheimers disease. Neurotox Res 7, 265-271.
56. Pratico D, Uryu K, Leight S, Trojanoswki JQ, LeeVM(2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21, 4183-4187. (Pubitemid 32538543)
57. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70, 2212-2215. (Pubitemid 28207848)
58. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M (2008) Oxidative stress activates a positive feedback between the gamma-and betasecretase cleavages of the beta-amyloid precursor protein. J Neurochem 104, 683-695.
59. House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta(42) in a manner which may have consequences for metal chelation therapy in Alzheimers disease. J Alzheimers Dis 6, 291-301. (Pubitemid 38823264)
60. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30, 447-450. (Pubitemid 32155543)
61. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, GiordanoT, GullansSR(2002) An iron-responsive element type II in the 5β-untranslated region of the Alzheimers amyloid precursor protein transcript. J Biol Chem 277, 45518-45528. (Pubitemid 36159162)
62. Bishop GM, Robinson SR (2004) The amyloid paradox: Amyloid-beta-metal complexes can be neurotoxic and neuroprotective. Brain Pathol 14, 448-452. (Pubitemid 39524973)
63. Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Hayashi Y, Nakayama K, Hayashi T (2007) Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry (Mosc) 46, 12737-12743. (Pubitemid 350064223)
64. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993) Cytotoxicity of microglia. Glia 7, 111-118.
65. Lynch MA (2009) The multifaceted profile of activated microglia. Mol Neurobiol 40, 139-156.
66. Moynagh PN (2005) The interleukin-1 signalling pathway in astrocytes: A key contributor to inflammation in the brain. J Anat 207, 265-269. (Pubitemid 41301001)
67. Mrak RE, Griffin WS (2001) Interleukin-1, neuroinflammation, and Alzheimers disease. Neurobiol Aging 22, 903-908.
68. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, OBanion MK (2007) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117, 1595-1604. (Pubitemid 46871344)
69. Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N (1992) Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: Modulation by interleukin-1. Brain Res Mol Brain Res 16, 128-134.
70. Griffin WS, Sheng JG, Roberts GW, Mrak RE (1995) Interleukin-1 expression in different plaque types in Alzheimers disease: Significance in plaque evolution. J Neuropathol Exp Neurol 54, 276-281.